Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lokelma to Enable ACEIs/ARBs Use in Diabetic Kidney Disease
ChiCTR2200057589Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sodium zirconium cyclosilicate in diabetic glomerulosclerosis and hyperkalemia (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Urine microalbumin/creatinine ratio, Serum biochemicals and 3 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
diabetic glomerulosclerosishyperkalemia
Beyond the preview
Go deeper on ChiCTR2200057589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057589.